What Did Jim Cramer Say About These 19 Stocks Recently?

Page 18 of 19

2. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Number of Hedge Fund Holders: 68

A caller asked about Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), and Cramer seemed optimistic, urging investors to be patient:

“I will tell you this, Regeneron, I want you to own it. I think it’s doing better than people realize. That is a good stock.”

Regeneron (NASDAQ:REGN) is a biotechnology company known for its innovative treatments in immunology and oncology. The company is advancing around 40 of its programs. It has relied on two primary products to drive top-line growth in the past years: Dupixent and Eylea. Dupixent is an eczema treatment whose rights Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares with Sanofi. Eylea, which Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) comarkets with Bayer, treats wet age-related macular generation.

Page 18 of 19